Skystar Bio-Pharma (SKBI) Cash Flow Statement

Click line-items for a historical chart and %

Net income	8.7M
Depreciation	1.25M
Amortization	186.51K
Bad debt expense	1.93M
Allowance for slow moving inventories
Common stock issued for services
Common stock to be issued to related parties for compensation
Change in fair value of warrant liability
Accounts receivable	-26.38M
Inventories	2.61M
Deposits and prepaid expenses	413.37K
Other receivables
Accounts payable	6.13M
Other payable and accrued expenses
Deposits from customers	-207.56K
Taxes payable	6.67M
Net cash (used in) provided by operating activities
Payments of long-term prepayments	-3.25M
Prepayment for asset acquisition
Loans to third parties
Collection of loans to third parties
Purchases of intangible assets
Purchases of plant and equipment	-8.65K
Payments on construction-in-progress	-827.88K
Net cash provided by (used in) investing activities
Proceeds from short-term loans	19.2M
Repayment for short-term loans
Repayment to shareholders and directors
Due (from) to related parties
Net cash provided by (used in) financing activities
EFFECT OF EXCHANGE RATE CHANGES ON CASH	-27.09K
DECREASE IN CASH	6.49M
CASH, beginning of period	8.14M
CASH, end of period	14.63M
Cash paid for interest	392.03K
Cash paid for income taxes	1.35M
Long-term prepayment transferred to construction-in-progress	3.49M
Long-term prepayment transferred to property, plant and equipment
Construction-in-progress transferred to property, plant and equipment	2.79M
Cashless exercise of warrants
Issuance of common stock accrued in previous year

Entities mentioned with SKBI

View All Entities